Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Tiseo M, Ippolito M, Scarlattei M, Spadaro P, Cosentino S, Latteri F, Ruffini L, Bartolotti M, Bortesi B, Fumarola C, Caffarra C, Cavazzoni A, Alfieri RR, Petronini PG, Bordonaro R, Bruzzi P, Ardizzoni A, Soto Parra HJ.
Tiseo M, et al. Among authors: ruffini l.
Cancer Chemother Pharmacol. 2014 Feb;73(2):299-307. doi: 10.1007/s00280-013-2356-x. Epub 2013 Nov 21.
Cancer Chemother Pharmacol. 2014.
PMID: 24258456
Clinical Trial.